Show simple item record

Forty years experience of treating cancer of unknown primary

dc.contributor.authorPavlidis, Nicholasen
dc.creatorPavlidis, Nicholasen
dc.date.accessioned2018-06-22T09:54:13Z
dc.date.available2018-06-22T09:54:13Z
dc.date.issued2007
dc.identifier.urihttps://gnosis.library.ucy.ac.cy/handle/7/42249
dc.description.abstractCancer of unknown primary site (CUP) is not a rare tumour. It accounts as the seventh to eighth most frequently diagnosed cancer in a general medical oncology service. Since CUP is not a homogeneous disease and it consists of different favourable and unfavourable sub-sets, treatment of each clinicopathological entity requires a unique approach. The spectrum of therapeutic management includes both locoregional and systemic therapy and should intend to offer optimal benefit to favourable CUP patients and palliative care to unfavourable cases. This review article provides both a historical outline of CUP treatment as well as a helpful therapeutic guide to every oncologist who treats CUP patients. © 2007 Taylor & Francis.en
dc.language.isoengen
dc.sourceActa Oncologicaen
dc.subjectBleomycinen
dc.subjectCancer chemotherapyen
dc.subjectCisplatinen
dc.subjectCyclophosphamideen
dc.subjectDacarbazineen
dc.subjectDoxorubicinen
dc.subjectEtoposideen
dc.subjectFluorouracilen
dc.subjectHumanen
dc.subjectMethotrexateen
dc.subjectNeoplasmsen
dc.subjectVinblastineen
dc.subjectVincristineen
dc.subjectHumansen
dc.subjectMammographyen
dc.subjectOncologyen
dc.subjectCancer survivalen
dc.subjectCarboplatinen
dc.subjectComputer assisted tomographyen
dc.subjectPaclitaxelen
dc.subjectPlatinum derivativeen
dc.subjectPriority journalen
dc.subjectPrognosisen
dc.subjectGemcitabineen
dc.subjectMonotherapyen
dc.subjectNavelbineen
dc.subjectTaxane derivativeen
dc.subjectDocetaxelen
dc.subjectErlotiniben
dc.subjectMetastasisen
dc.subjectCancer diagnosisen
dc.subjectSurvival rateen
dc.subjectCarmustineen
dc.subjectEpirubicinen
dc.subjectFolinic aciden
dc.subjectIrinotecanen
dc.subjectConference paperen
dc.subjectAxillary lymph nodeen
dc.subjectMitomycin cen
dc.subjectLymph node metastasisen
dc.subjectOncogeneen
dc.subjectDrug megadoseen
dc.subjectCarcinogenesisen
dc.subjectProstate canceren
dc.subjectPathologyen
dc.subjectLymphadenopathyen
dc.subjectNuclear magnetic resonance imagingen
dc.subjectTreatment responseen
dc.subjectAnthracycline derivativeen
dc.subjectBevacizumaben
dc.subjectAdenocarcinomaen
dc.subjectAltretamineen
dc.subjectPractice guidelineen
dc.subjectSquamous cell carcinomaen
dc.subjectCombination chemotherapyen
dc.subjectUnknown primaryen
dc.subjectAngiogenesisen
dc.subjectCancer palliative therapyen
dc.subjectProstate specific antigenen
dc.subjectNeuroendocrine tumoren
dc.subjectCervical lymph nodeen
dc.subjectPeritoneum canceren
dc.subjectMultimodality cancer therapyen
dc.subjectMedical specialisten
dc.subjectDrug dose comparisonen
dc.subjectChromosome aberrationen
dc.subjectTumor suppressor geneen
dc.subjectProtein degradationen
dc.subjectCancer epidemiologyen
dc.subjectBlast cell crisisen
dc.subjectCancer of unknown primaryen
dc.subjectGranulocyte colony stimulating factor receptoren
dc.subjectPapillary carcinomaen
dc.subjectSparfosic aciden
dc.titleForty years experience of treating cancer of unknown primaryen
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1080/02841860701243095
dc.description.volume46
dc.description.issue5
dc.description.startingpage592
dc.description.endingpage601
dc.author.facultyΙατρική Σχολή / Medical School
dc.author.departmentΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen
dc.contributor.orcidPavlidis, Nicholas [0000-0002-2195-9961]
dc.gnosis.orcid0000-0002-2195-9961


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record